Competition in prescription drug markets: The roles of trademarks, advertising, and generic names

European Journal of Health Economics

Volumn 14, Issue 4, 2013, Pages 667-675

  Feldman, Roger ^a   Lobo, Félix ^b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSIDAD CARLOS III DE MADRID   (Spain)

Author keywords

Advertising; Generic names; Prescription drug markets; Trademarks

Indexed keywords

ACETYLSALICYLIC ACID; DEXTROPROPOXYPHENE; GENERIC DRUG; PRESCRIPTION DRUG;

ARTICLE; COMPETITION; CONSUMER; DRUG LABELING; DRUG MARKETING; DRUG NOMENCLATURE; DRUG QUALITY; MEDICAL LITERATURE; PATENT; PRESCRIPTION; PRIORITY JOURNAL; PURCHASING;

ADVERTISING AS TOPIC; DRUG COSTS; DRUG INDUSTRY; DRUGS, GENERIC; ECONOMIC COMPETITION; HUMANS; MODELS, THEORETICAL; PATENTS AS TOPIC; PRESCRIPTION DRUGS;

EID: 84879930603     PISSN: 16187598     EISSN: 16187601     Source Type: Journal    
DOI: 10.1007/s10198-012-0414-7     Document Type: Article

References (53)

1. Appelt, S.: Early Entries and Trademarks - Barriers to Generic Entry in the German Pharmaceutical Industry? Paper presented at the DRUID-DIME Academy Winter 2009 PhD Conference, viewed at http://www2.druid.dk/conferences/ viewabstract.php?id=4403&cf=33. June 5, 2011 (2009)
2. Berndt, E.R.; Kyle, M.K.; Ling, D.C.: The long shadow of patent expiration: Generic entry and Rx-to-OTC switches. In: Feenstra, R.C.; Shapiro, M.D. (eds.) Scanner data and price indices. University of Chicago Press, Chicago (2003)
3. Berndt, E.R.; Aitken, M.L.: Brand loyalty, generic entry and price competition in pharmaceuticals in the quarter century after the 1984 Waxman-Hatch legislation. Int. J. Econom. Business 18(2), 177-201 (2011)
4. Boland, G.L.: Federal regulation of prescription drug advertising and labeling. Boston College Law Rev. 12(2), 203-266 (1970)
5. Bond, R.S.; Lean, D.S.: Sales, promotion and product differentiation in two prescription drug markets. Staff Report, Bureau of Economics. US Federal Trade Commission, Washington, DC (1977)
6. Carlton, D.W.; Perloff, J.M.: Modern industrial organization. Foresman, Glenview (1990). Appendix 18A
7. Caves, R.E.; Whinston, M.D.; Hurwitz, M.A.; Pakes, A.; Temin, P.: Patent expiration, entry and competition in the US pharmaceutical industry. Brookings Papers on Economic Activity: Microeconomics, pp. 1-66. Brookings Institution, Washington, DC (1991)
8. Chamberlin, E.H.: The theory of monopolistic competition. Harvard University Press, Cambridge (1933)
9. Ching, A.T.: A dynamic oligopoly structural model for the prescription drug market after patent expiration. Int. Econom. Rev. 51(4), 1175-1207 (2010)
10. Dorfman, R.; Steiner, P.O.: Optimal advertising and optimal product quality. Am. Econom. Rev. 44, 826-836 (1954)
11. Economides, N.S.: The economics of trademarks. Trademark Rep. 78(4), 523-539 (1988)
12. Fanfan-Portet, M.-I.; Van de Voorde, C.; Vrijens, F.; Stichele, R.V.: Patient socioeconomic determinants of the choice of generic versus brand name drugs in the context of a reference price system: Evidence from Belgian prescription data. Eur. J. Health Econ. 13(3), 301-313 (2012)
13. Frank, R.G.: The ongoing regulation of generic drugs. New Engl. J. Med. 357(20), 1993-1996 (2007)
14. Frank, R.G.; Salkever, D.S.: Generic entry and the pricing of pharmaceuticals. J. Econom. Manage. Strat. 6(1), 75-90 (1997)
15. Gorecki, P.: The importance of being first: the case of prescription drugs in Canada. Int. J. Ind. Organ. 4, 371-395 (1986)
16. Gorecki, P.: Barriers to entry in the canadian pharmaceutical industry: Comments, clarifications and extensions. J. Health Econ. 6, 59-72 (1987)
17. Grabowski, H.G.; Vernon, J.M.: Brand loyalty, entry and price competition in pharmaceuticals after the 1984 Drug Act. J. Law Econ. 35, 331-350 (1992)
18. Grabowski, H.G.; Vernon, J.M.: Longer patents for increased generic competition in the US: The Waxman-Hatch act after one decade. Pharmacoeconomics 10(Suppl. 2), 110-123 (1996)
19. Hollis, A.: The importance of being first: Evidence from Canadian generic pharmaceuticals. J. Health Econ. 11, 723-734 (2002)
20. Huckfeldt, P.J.; Knittel, C.R.: Pharmaceutical use following generic entry: paying less and buying less. Cambridge, MA: National Bureau of Economic Research, Working Paper 17046, viewed at http://www.nber.org/papers/w17046, accessed 17 April 2012 (2011)
21. Hurwitz, M.A.; Caves, R.E.: Persuasion or information? Promotion and the shares of brand name and generic pharmaceuticals. J. Law Econ. 31, 299-320 (1988)
22. Kavanos, P.; Costa-Font, J.; Seeley, E.: "Competition in off-patent drug markets: Issues. Regulation and Evidence, Economic Policy 23(55), 499-544 (2008)
23. Königsbauer, I.: Advertising and generic market entry. J. Health Econ. 26, 286-305 (2007)
24. Lambert, B.L.; Lin, S.-J.; Chang, Ken.-Yu.; Gandhi, S.K.: Similarity as a risk factor in drug name confusion errors: The look-alike (Orthographic) and sound-alike (Phonetic) model. Med. Care 37(12), 1214-1225 (1999)
25. Landes, W.M.; Posner, R.A.: Trademark law: an economic perspective. J. Law Econ. 30(2) (October), pp. 265-309. An adaptation (with no equations) is "The Economics of Trademark Law," The Trademark Reporter, 78(3), 1988, 267-306 (1987)
26. Leffler, K.B.: Persuasion or information? The economics of prescription drug advertising. J. Law Econ. 24, 45-74 (1981)
27. Lexchin, J.: The effect of generic competition on the price of brand-name drugs. Health Policy 68, 47-54 (2004)
28. Lobo, F.; Feldman, R.: Generic Drug Names and Social Welfare. Department of Economics, Universidad Carlos III de Madrid, working paper (2011)
29. López-Casasnovas, G.; Puig-Junoy, J.: Review of the literature on reference pricing. Health Policy 54(2), 87-123 (2000)
30. Masson, A.; Steiner, R.L.: Generic substitution and prescription drug prices: economic effects of state drug product selection laws. US Federal Trade Commission, Bureau of Economics, Washington, DC (1985)
31. McClure, D.M.: Trademarks and competition: the recent history. Law and Contemporary Problems 59(2), 13-43 (1996)
32. McRae, J.J.; Tapon, F.: Some empirical evidence on post-patent barriers to entry in the Canadian pharmaceutical industry. J. Health Econ. 4, 43-61 (1985)
33. Mestre Ferrándiz, J.: The impact of generic goods in the pharmaceutical industry. Health Econ. 8, 599-612 (1999)
34. Oberender, P.: Europe's drug market and pharmaceutical industry in the 1990s. In: Barfield, C.E.; Perlman, M. (eds.) Ch 5 in Industry Services and Agriculture: The United States Faces a United Europe. University Press of America, Lanham (1992)
35. Posner, R.A.: Intellectual property: the law and economics approach. J. Econom. Perspect. 19(2), 57-73 (2005)
36. Ramello, G.B.: What's in a name: trademark law and economic theory. J. Econom. Surv. 20(4), 547-565 (2006)
37. Regan, T.L.: Generic entry, price competition, and market segmentation in the prescription drug market. Int. J. Ind. Organ. 26(4), 930-948 (2008)
38. Reiffen, D.; Ward, M.R.: Generic drug industry dynamics. Rev Econ Stat 87(1), 37-49 (2005)
39. Saha, A.; Grabowski, H.; Birnbaum, H.; Greenberg, P.; Bizan, O.: Generic competition in the US pharmaceutical industry. International Journal of Economics of Business 13(1), 15-38 (2006)
40. Saul, S.: Drug ads raise questions for heart pioneer. New York Times, viewed at http://www.nytimes.com, accessed 7 June 2012 (2008)
41. Scherer, F.M.: Industrial market structure and economic performance. Rand McNally, Chicago (1970)
42. Scherer, F.M.: Post-patent barriers to entry in the pharmaceutical industry. J. Health Econ. 4, 83-87 (1985)
43. Scherer, F.M.: Pricing, profits and technological progress in the pharmaceutical industry. J. Econom. Perspect. 7, 97-115 (1993)
44. Scherer, F.M.; Ross, D.: Industrial market structure and economic performance, 3rd edn. Houghton Mifflin, Boston (1990)
45. Schmalensee, R.: Entry deterrence in the ready-to-eat breakfast cereal market. Bell Journal of Economics 9(2), 305-327 (1978)
46. Schmalensee, R.: Product differentiation advantages of pioneering brands. American Economic Review 72, 349-365 (1982)
47. Scott Morton, F.M.: Barriers to entry, brand advertising, and generic entry in the U.S. pharmaceutical industry. Int. J. Ind. Organ. 18(7), 1085-1104 (2000)
48. Scott Morton, F.M.: Horizontal integration between brand and generic firms in the pharmaceutical industry. J. Econom. Manage. Strat. 11(1), 135-168 (2002)
49. Steele, H.: Monopoly and competition in the ethical drugs market. J. Law Econ. 5, 131-164 (1962)
50. US Congressional Budget Office (CBO).: How increased competition from generic drugs has affected prices and returns in the pharmaceutical industry, July, Washington, DC (1998)
51. US Congress Senate Kefauver Hearings.: Refers to United States Congress, Senate Committee on the Judiciary, Subcommittee on Antitrust and Monopoly (Chairman Senate E. Kefauver: Administered Prices in the Drug Industry, Parts 14-26, Washington, DC: USGPO (1959-1960)
52. Walker, H.D.: Market power and price levels in the ethical drug industry. Indiana University Press, Bloomington (1971)
53. World Health Organization: Expert Committee on the Unification of Pharmacopeias, Report on the Sixth Session, Technical Report Series No. 29, Geneva: WHO (1950)